Published in Pharma Law Weekly, January 18th, 2005
Macugen helps preserve vision and helps limit progression to legal blindness. Approval of Macugen follows a priority review under the FDA's rolling submission-Pilot 1 program based on data from the companies' phase II/III pivotal clinical trials.
Macugen is the first in a new class of ophthalmic drugs to specifically target vascular...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly